- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Value of Subcutaneous Therapy for Patients
Panelists discuss how SC delivery enhances patient convenience and health care efficiency in NSCLC treatment.
EP: 1.Understanding EGFR Mutations and First-Line Treatment
EP: 2.Overcoming Resistance Mechanisms and Addressing Unmet Needs
EP: 3.Impact of Recent Approvals and Novel Mechanisms
EP: 4.CNS Penetration and Efficacy of Emerging Therapies
EP: 5.Managing Adverse Events and Integrating Amivantamab Plus Lazertinib
EP: 6.Sequencing Therapies and Using the Most Effective Options First
EP: 7.The Value of Subcutaneous Therapy for Patients
EP: 8.FDA Approvals, Patient Selection, and SC Amivantamab
Panelists discuss how subcutaneous (SC) delivery is transforming oncology care by improving efficiency and patient convenience. They outline how SC formulations reduce infusion chair time, streamline scheduling, and ease strain on health care resources amid workforce shortages. The discussion underscores that SC administration enhances patient satisfaction through shorter visits and less invasive care while providing operational benefits for clinics. SC formulations are positioned as a modern solution for balancing clinical outcomes with system-wide efficiency.
Brensocatib Improves Outcomes in Non-Cystic Fibrosis Bronchiectasis With or Without Comorbid COPD
November 8th 2025Brensocatib improves lung structure and reduces exacerbations in non-cystic fibrosis bronchiectasis with or without COPD, according to posters presented at this year's CHEST meeting.
Read More
